Shares of CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) fell 13.7% during mid-day trading on Tuesday . The stock traded as low as $2.77 and last traded at $2.96. 313,428 shares traded hands during trading, a decline of 89% from the average session volume of 2,783,089 shares. The stock had previously closed at $3.43.
Wall Street Analyst Weigh In
Separately, Benchmark reissued a “speculative buy” rating and set a $5.00 price objective on shares of CytoMed Therapeutics in a report on Thursday, October 10th.
View Our Latest Stock Report on CytoMed Therapeutics
CytoMed Therapeutics Stock Down 13.7 %
About CytoMed Therapeutics
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Further Reading
- Five stocks we like better than CytoMed Therapeutics
- Differences Between Momentum Investing and Long Term Investing
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- How Investors Can Find the Best Cheap Dividend Stocks
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- 3 Small Caps With Big Return Potential
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
